Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (NASDAQ: CVKD) reported Q1 2026 results and FDA End-of-Phase 2 minutes for CAD-1005 in suspected heparin-induced thrombocytopenia (HIT). The company plans a randomized, blinded, placebo-controlled pivotal Phase 3 (~120 patients) to support a projected NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulation. Q1 operating loss was $2.5M; cash was $2.3M as of March 31, 2026, and a $2.5M financing closed April 1, 2026.
Cadrenal Therapeutics (Nasdaq: CVKD) reported completion of an End-of-Phase 2 meeting with the FDA and received guidance to advance CAD-1005 into a pivotal Phase 3 registration trial for heparin-induced thrombocytopenia (HIT).
The planned randomized, blinded, placebo-controlled Phase 3 will enroll ~120 patients across up to 50 centers, treat patients up to 14 days on background anticoagulant therapy, use centrally adjudicated incidence of new or worsening thrombotic events in SRA-confirmed HIT as the primary endpoint, include at least one interim analysis, and targets an NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Q4 and full-year results and provided an update on CAD-1005 for suspected heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026, reported Phase 2 data showing a >25% absolute reduction in thrombotic events, and is incorporating FDA feedback into a planned Phase 3 pivotal protocol.
Cadrenal held $4.0 million cash at December 31, 2025, reported a Q4 net loss of $3.0 million, and is evaluating financing and strategic alternatives to support clinical development.
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted research supporting its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, as a potential approach to reduce obesity- and Type 2 diabetes‑related inflammation. Preclinical oral dosing showed improved glycemic control, preserved pancreatic β-cells, fewer inflammatory cells in adipose and pancreas, and lower adipose pro-inflammatory cytokines. Cadrenal acquired the 12-LOX portfolio in December 2025 and reported Phase 2 results showing reduced thrombotic events in suspected HIT. The company is developing next-generation CAD-2000.
Cadrenal Therapeutics (Nasdaq: CVKD) expanded its pipeline with a portfolio of selective 12-LOX inhibitors, including oral candidates, and reported encouraging blinded Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia (HIT).
CAD-1005 showed a reduction in thrombotic events on standard anticoagulants and an End-of-Phase 2 (EOP-2) meeting is scheduled this month (March 2026). Management positions 12-LOX inhibition as a differentiated platform with potential acute and chronic applications across inflammatory and thrombotic diseases.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT) showing a >25% absolute reduction in thrombotic events versus placebo on top of standard anticoagulant therapy, despite no improvement in platelet count recovery. An End-of-Phase 2 FDA meeting is scheduled for March 2026 to align on a Phase 3 path. The trial was randomized, blinded, placebo-controlled and concluded in December 2025 after program transfer from Veralox. Detailed data will be presented at a future scientific meeting.
Cadrenal Therapeutics (NASDAQ: CVKD) highlighted the high incidence and clinical burden of thrombotic complications in heparin-induced thrombocytopenia (HIT) and promoted VLX-1005—acquired in December 2025—as the first highly selective 12-LOX inhibitor in clinical testing. Emerging Phase 2 data suggest VLX-1005 may reduce thrombotic complications in suspected HIT by targeting immune-driven platelet activation rather than only inhibiting coagulation.
VLX-1005 has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA; Cadrenal plans FDA discussions about a potential pivotal Phase 3 registration study. Cadrenal will also present at Lytham Partners on January 15, 2026.
Cadrenal Therapeutics (NASDAQ:CVKD) is positioning its pipeline as a hospital-focused anticoagulation platform on December 30, 2025. The company pairs a Phase 3-ready vitamin K antagonist, tecarfarin, aimed at renal-impaired and dialysis patients, with an acquired Factor XIa inhibitor portfolio for acute hospital care. Cadrenal also holds VLX-1005, a Phase 2 12-LOX inhibitor with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT). Together the assets span chronic, acute, and immune-mediated anticoagulation failures, targeting high-acuity hospital needs rather than broad-market incremental gains.
Cadrenal Therapeutics (NASDAQ:CVKD) is pursuing underserved anticoagulation patients with a three‑pillar pipeline targeting chronic, acute, and immune‑mediated thrombosis.
Key elements: a Phase 3‑ready vitamin K antagonist tecarfarin designed for kidney‑impaired and dialysis patients; an acquired Factor XIa inhibitor portfolio for acute hospital care; and VLX‑1005, a Phase 2 12‑LOX inhibitor for heparin‑induced thrombocytopenia with Orphan Drug and Fast Track designations.
The company positions this asset mix as a purpose‑built platform to address high‑risk patients where existing anticoagulants perform poorly.
Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.
Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).